Redx's discovery of Pirtobrutinib recognised with unveiling of commemorative plaque
Redx , the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease confirms that a commemorative plaque has been unveiled by Bruntwood SciTech at their Alderley Park campus, where Redx is headquartered, in recognition of the team's discovery of pirtobrutinib[1], the active pharmaceutical ingredient (API) in Eli Lilly's Jaypirca™[2].Redx , the clinical-stage